Pioglitazone Decreases Type 2 Diabetes Risk in Stroke Patients with Insulin Resistance #2016ADA
Pioglitazone greatly decreases the risk of developing type 2 diabetes, especially for those who already have prediabetes and/or who have had strokes, according to a study presented at the American Diabetes Association’s 76th Scientific Sessions® at the Ernest N. Morial Convention Center in New Orleans. The Insulin Resistance Intervention after Stroke trial (IRIS)[1]
Continua a leggere